BioCardia CEO buys 5,700 company shares

BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,700 shares of Common Stock at a weighted average price of $0.92 per share.

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,700 shares of Common Stock at a weighted average price of $0.92 per share. Following this transaction, he directly holds 291,566 shares. The trade was executed in multiple lots between $0.89 and $1.02 per share.

Insider Trade Summary

Net Buyer: 5,700 shares

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 5,700 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,700	$0.92	$5K

Holdings After Transaction: Common Stock — 291,566 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades ranging from $0.89 to $1.02 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased: 5,700 shares Weighted average price: $0.92 per share Post-transaction holdings: 291,566 shares +2 more

5 metrics

Shares purchased 5,700 shares Open-market buy of Common Stock

Weighted average price $0.92 per share Price for 5,700-share purchase

Post-transaction holdings 291,566 shares Direct Common Stock owned after purchase

Price range of trades $0.89–$1.02 per share Range for multiple executions in this transaction

Net buy shares 5,700 shares Net change in buy/sell activity in this Form 4

Key Terms

open-market purchase, weighted average per share sales price, Common Stock, Reporting Person

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average per share sales price financial

"The price reported above reflects the weighted average per share sales price."

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Reporting Person regulatory

"The Reporting Person hereby undertakes to provide upon request"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioCardia (BCDA) report for Peter Altman?

BioCardia reported that President and CEO Peter Altman bought 5,700 shares of Common Stock in an open-market purchase. The filing shows this insider acquisition occurred at a weighted average price of $0.92 per share across multiple trade executions.

At what prices did the BioCardia (BCDA) CEO’s recent share purchases occur?

Peter Altman’s 5,700-share purchase was executed in multiple trades ranging from $0.89 to $1.02 per share. The Form 4 reports a weighted average transaction price of $0.92 per share for this open-market acquisition of BioCardia Common Stock.

How many BioCardia (BCDA) shares does Peter Altman own after this transaction?

After the reported open-market purchase, Peter Altman directly owns 291,566 shares of BioCardia Common Stock. This total reflects his holdings immediately following the 5,700-share acquisition disclosed in the Form 4 insider trading report filed with regulators.

Was the BioCardia (BCDA) CEO’s recent transaction a purchase or a sale?

The transaction was a purchase. The Form 4 classifies it under code P, indicating an open-market or private purchase, and the normalized data flags the direction as a buy, confirming that Peter Altman increased his direct Common Stock holdings.

How is the transaction price reported for BioCardia (BCDA) CEO’s Form 4 trade?

The transaction price is reported as a weighted average of $0.92 per share. A footnote explains the trade was executed in multiple lots between $0.89 and $1.02, and the reporting person can provide detailed price breakdowns upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 08:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		P		5,700(1)	A	$0.92(1)	291,566	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.89 to $1.02 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)